Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCamellia Regulatory News (CAM)

Share Price Information for Camellia (CAM)

Share Price is delayed by 15 minutes
Get Live Data
5,450.00    -50.00 (-0.91%)
Bid:
5,400.00
Ask:
5,450.00
Spread: 50.00 (0.926%)
Market Cap: £137.76m
CAM Live PriceLast checked at - London Stock Exchange

Intraday Camellia Share Chart

BF&M Strategic Review Conclusion

30 Jan 2023 07:00

RNS Number : 1765O
Camellia PLC
30 January 2023
 

30 January 2023

Camellia Plc

 

(the "Company" or the "Group")

 

Associate Company Update

 

Camellia Plc (CAM.L) notes that its 36.9% owned associate company, BF&M Limited ("BF&M"), a listed Bermudian insurance business, has issued a statement that it has concluded its previously announced strategic review. The BF&M Board has determined that continuing to execute its strategic plan on a standalone basis is in the best interest of all BF&M shareholders, that BF&M remains in a strong capital position, has the right strategic plan already in place and a foundation for growth. BF&M remains focussed on taking decisive steps to create value for its shareholders. The full text of BF&M's announcement can be found in Appendix 1 to this announcement.

 

 

Enquiries

 

Camellia Plc 01622 746655

Malcolm Perkins, Chairman

Susan Walker, Chief Financial Officer

 

Panmure Gordon 020 7886 2500

Nominated Adviser and Broker

Emma Earl

Rupert Dearden

 

Maitland/AMO

PR

William Clutterbuck 07785 292617

 

 

 

  

Appendix 1

BF&M Concludes Strategic Review

 

Hamilton, Bermuda, 7 December 2022 - BF&M Limited ("BF&M", "the BF&M Group" or "the Company") today announced that its Board of Directors (the "Board") concluded its previously announced review of strategic alternatives (the "Strategic Review"). After a comprehensive process with the assistance of Desjardins Capital Markets, the Board has determined that continuing to execute its strategic plan on a standalone basis is in the best interest of all shareholders.

 

Anthony Joaquin, Acting Chairman of the Board, said, "During our review, the Board assessed a comprehensive range of potential outcomes. Ultimately, this process reinforced our confidence that BF&M has the right strategic plan already in place to maximize value for shareholders. With this evaluation concluded, the Board is fully committed to supporting Abigail and the rest of the Company's leadership team as they continue to execute this plan."

 

Abigail Clifford, Chief Executive Officer, said, "BF&M is entering 2023 with a strong capital position and foundation for growth, including the highest AM Best financial strength rating of any domestic insurers operating in Bermuda and the Caribbean. We remain focused on taking decisive steps to create value for shareholders, while providing best-in-class support to our clients as they navigate a challenging economic environment and positioning BF&M as an employer of choice."

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBKLLLXFLFBBF
Date   Source Headline
4th Jun 202612:31 pmRNSResult of AGM
22nd May 20267:00 amRNSSale of Chalouni Tea Estate
5th May 20267:00 amRNSFinal Results
7th Apr 20264:19 pmRNSProposed Sale of Chalouni Tea Estate
1st Apr 20267:00 amRNSArtwork Sale and Update on Indian Tea Estate MOU
23rd Feb 20267:00 amRNSTrading Update
23rd Jan 20267:00 amRNSDirectorate change
27th Nov 20257:00 amRNSKakuzi Land Claims
8th Sep 20254:47 pmRNSDirector/PDMR Shareholding
5th Sep 20257:00 amRNSHalf Year Results
26th Aug 20257:00 amRNSNotice of Half Year Results
4th Jul 20254:30 pmRNSDisposal
13th Jun 20254:01 pmRNSHolding(s) in Company
13th Jun 20252:35 pmRNSHolding(s) in Company
10th Jun 20259:09 amRNSHolding(s) in Company
9th Jun 20254:39 pmRNSHolding(s) in Company 9 June 2025
6th Jun 20257:00 amRNSResult of Tender Offer
5th Jun 20252:02 pmRNSResult of General Meetings
19th May 20257:00 amRNSValue Enhancement Plan
19th May 20257:00 amRNSTender Offer
13th May 20257:00 amRNSHolding(s) in Company
9th May 20257:00 amRNSTransaction in Own Shares
8th May 20257:00 amRNSValue Enhancement Plan Date & Presentation
30th Apr 20257:00 amRNSFinal Results
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20257:00 amRNSPotential Disposal
15th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20259:07 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
17th Mar 20257:00 amRNSTransaction in Own Shares
13th Mar 20257:00 amRNSDisposal
11th Mar 20257:00 amRNSTransaction in Own Shares
5th Mar 20257:00 amRNSTransaction in Own Shares
4th Mar 20257:00 amRNSTransaction in Own Shares
26th Feb 20257:00 amRNSTransaction in Own Shares
25th Feb 20257:00 amRNSTransaction in Own Shares
20th Feb 20257:00 amRNSTransaction in Own Shares
17th Feb 20257:00 amRNSTransaction in Own Shares
12th Feb 20257:00 amRNSPotential Disposal
11th Feb 20257:00 amRNSTransaction in Own Shares
10th Feb 20257:00 amRNSTransaction in Own Shares
7th Feb 20257:00 amRNSTransaction in Own Shares
6th Feb 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.